Continuation of research and development activities
First written in FY2017-Q1. 26 of 36 entries say "Restated". Latest entry: FY2027-H1.
56 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「At a Board of Directors meeting held on 13 April 2026, the Company resolved to make the following capital investment. 1. Purpose of the capital investment: To strengthen research and development capabilities. 2. Details of the capital investment: (1) Name: Research and Development Center (Mirai Lab)」
While continuing its research and development activities, the Company resolved to establish a Research and Development Center (Mirai Lab) to strengthen its research and development capabilities. The disclosure states that ¥748 million has already been paid and that completion is scheduled for April 2029 or later. - 2026-10-09AdvancedEarnings
「The purpose is to strengthen our research and development capabilities.」
The company resolved to invest in facilities for its R&D Center (Mirai Lab) to strengthen its research and development capabilities, reporting ¥748 million already paid and completion scheduled for April 2029 or later. - FY2026Fewer R&D personnel and higher costsAnnual report
「The staff engaged in these R&D activities totaled 37 across the Group, equivalent to 2.2% of total personnel, including employees and temporary workers. The total R&D expenses for the consolidated fiscal year were ¥431 million.」
R&D expenses increased from ¥417 million in the previous fiscal year to ¥431 million, while R&D staff decreased from 40, or 2.4%, to 37, or 2.2%. The R&D activities themselves are continuing. - FY2026-H1RestatedAnnual report
「The Group's total R&D expenses for the interim consolidated accounting period were ¥213 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The company continues its research and development activities and reports R&D expenses of ¥213 million for the interim period, while stating that there have been no material changes in the status of these activities. - FY2025Lower R&D personnel, ratio and expensesAnnual report
「The staff engaged in these R&D activities totaled 39 across the Group, equivalent to 2.3% of total personnel, including employees and temporary workers. The total R&D expenses for the consolidated fiscal year were ¥417 million.」
R&D staff decreased from 40, or 2.4%, in the previous fiscal year to 39, or 2.3%, while R&D expenses decreased from ¥425 million to ¥417 million. The R&D activities themselves are continuing. - FY2025-H1RestatedAnnual report
「The Group's total R&D expenses for the interim consolidated accounting period were ¥210 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The company continues its research and development activities and reports R&D expenses of ¥210 million for the interim period, while stating that there have been no material changes in the status of these activities. - FY2025-Q1RestatedAnnual report
「The Group's total R&D expenses for the three-month consolidated period were ¥101 million. There were no material changes in the status of the Group's R&D activities during the three-month consolidated period.」
The company continues its research and development activities and reports R&D expenses of ¥101 million for the three-month period. It states that there have been no material changes in the status of these activities. - FY2024-Q3RestatedAnnual report
「The Group's total R&D expenses for the nine-month consolidated period were ¥314 million. There were no material changes in the status of the Group's R&D activities during the nine-month consolidated period.」
The company continues its research and development activities and reports R&D expenses of ¥314 million for the nine-month period. It states that there have been no material changes in the status of these activities. - FY2024-Q2RestatedAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥214 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
The company continues its research and development activities and reports R&D expenses of ¥214 million for the six-month period. It states that there have been no material changes in the status of these activities. - FY2024-Q1RestatedAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥102 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
The company continues its research and development activities and reports R&D expenses of ¥102 million for the first nine-month period. It states that there have been no material changes in the status of these activities. - FY2023Higher R&D expenses, fewer personnelAnnual report
「The staff engaged in these R&D activities totaled 40 across the Group, equivalent to 2.4% of total personnel, including employees and temporary workers. The total R&D expenses for the consolidated fiscal year were ¥425 million.」
R&D staff decreased from 42, or 3.2%, in the previous fiscal year to 40, or 2.4%, while R&D expenses increased from ¥400 million to ¥425 million. - FY2023-Q3RestatedAnnual report
「The Group's total R&D expenses for the nine-month consolidated period were ¥294 million. There were no material changes in the status of the Group's R&D activities during the nine-month consolidated period.」
The company continues its research and development activities and reports R&D expenses of ¥294 million for the nine-month period. It states that there have been no material changes in the status of these activities. - FY2023-Q1RestatedAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥99 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
The company continues its research and development activities and reports R&D expenses of ¥99 million for the quarter. It states that there have been no material changes in the status of these activities. - FY2022More R&D personnel and lower costsAnnual report
「The staff engaged in these R&D activities totaled 42 across the Group, equivalent to 3.2% of total employees. Total R&D expenditure for the fiscal year was ¥400 million.」
R&D staff increased from 41, or 3.0% of total employees, in the previous fiscal year to 42, or 3.2%, while R&D expenditure declined from ¥459 million to ¥400 million. - FY2022-Q3RestatedAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥354 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
R&D activities continued, with R&D expenditure for the nine months ended the third quarter reported at ¥354 million, while the company stated that there were no material changes in the status of those activities. - FY2022-Q2RestatedAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥209 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
R&D activities continued, with R&D expenditure for the six months ended the second quarter reported at ¥209 million, while the company stated that there were no material changes in the status of those activities. - FY2022-Q1RestatedAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥100 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
R&D activities continued, with quarterly R&D expenditure reported at ¥100 million. The company stated that there were no material changes in the status of those activities. - FY2021AdvancedAnnual report
「The staff engaged in these R&D activities totaled 41 across the Group, equivalent to 3.0% of total employees. Total R&D expenditure for the fiscal year was ¥459 million.」
R&D staff increased to 41 from 39, representing 3.0% versus 2.9% of total employees, while R&D expenditure increased to ¥459 million from ¥398 million, indicating a larger scale of investment. - FY2021-Q3RestatedAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥357 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company reported cumulative R&D expenditure of ¥357 million for the nine months ended the third quarter and stated that there were no material changes in the status of its R&D activities. - FY2021-Q2RestatedAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥207 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
R&D activities continued, with R&D expenditure for the six months ended the second quarter reported at ¥207 million. The company stated that there were no material changes in the status of those activities. - FY2021-Q1RestatedAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥102 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
R&D activities continued, with quarterly R&D expenditure reported at ¥102 million, while the company stated that there were no material changes in the status of those activities. - FY2020AdvancedAnnual report
「The staff engaged in these R&D activities totaled 39 across the Group, equivalent to 2.9% of total employees. Total R&D expenditure for the fiscal year was ¥398 million.」
The company reported 39 R&D staff, representing 2.9% of total employees, and R&D expenditure of ¥398 million, and continued its R&D activities. - FY2020-Q3RestatedAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥293 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
R&D activities continued, with expenditure for the period reported at ¥293 million, while the company stated that there were no material changes in the status of those activities. - FY2020-Q2RestatedAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥195 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
R&D activities continued, with expenditure for the period reported at ¥195 million, while the company stated that there were no material changes in the status of those activities. - FY2020-Q1RestatedAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥95 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
R&D activities continued, with quarterly R&D expenditure reported at ¥95 million, while the company stated that there were no material changes in the status of those activities. - FY2019RestatedAnnual report
「The staff engaged in these R&D activities totaled 36 across the Group, equivalent to 2.7% of total employees. Total R&D expenditure for the fiscal year was ¥409 million.」
The company reported 36 R&D staff, representing 2.7% of total employees, and R&D expenditure of ¥409 million as its R&D resources and investment. - FY2019-Q3RestatedAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥313 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
R&D activities continued, with cumulative R&D expenditure for the nine months ended the third quarter reported at ¥313 million, while the company stated that there were no material changes in the status of those activities. - FY2019-Q2RestatedAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥214 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
R&D activities continued, with expenditure for the period reported at ¥214 million, while the company stated that there were no material changes in the status of those activities. - FY2019-Q1RestatedAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥99 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
R&D activities continued, with quarterly R&D expenditure reported at ¥99 million, while the company stated that there were no material changes in the status of those activities. - FY2018RestatedAnnual report
「The Group's basic policy is to provide high-value-added products with distinctive features at reasonable prices while meeting diversifying customer needs. To achieve this objective, the Group conducts R&D activities with the following areas as its main focus.」
The Group continues R&D activities centered on meeting customer needs, developing high-value-added products, energy conservation and streamlining, automation and labor saving, hygiene improvements, enhancements to existing products, and technical guidance for overseas partner factories. - FY2018-Q3RestatedAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥293 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
R&D activities continued, with expenditure for the period reported at ¥293 million, while the company stated that there were no material changes in the status of those activities. - FY2018-Q2RestatedAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥188 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
R&D activities continued, with expenditure for the period reported at ¥188 million, while the company stated that there were no material changes in the status of those activities. - FY2018-Q1RestatedAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥97 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
R&D activities continued, with quarterly R&D expenditure reported at ¥97 million, while the company stated that there were no material changes in the status of those activities. - FY2017AdvancedAnnual report
「The staff engaged in these R&D activities totaled 39 across the Group, equivalent to 3.0% of total employees. Total R&D expenditure for the fiscal year was ¥417 million.」
The company continued its R&D activities, with 39 R&D staff representing 3.0% of total employees and R&D expenditure of ¥417 million, and launched multiple new and improved products. - FY2017-Q2RestatedAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥205 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
R&D activities continued, with expenditure for the period reported at ¥205 million, while the company stated that there were no material changes in the status of those activities. - FY2017-Q1First statedAnnual report
「Group-wide research and development expenditures for the first quarter cumulative period were ¥101 million. There were no material changes in the status of the Group's research and development activities during the first quarter cumulative period.」
R&D activities continued, with expenditure for the quarter amounting to ¥101 million.